The current management of Alzheimer's disease (AD) focuses on acetylcholinesterase inhibitors (AChEIs) and NMDA receptor antagonists, although outcomes are not completely favorable. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.